India emerges as new drug trial hot spot
India emerges as new drug trial hot spot
Biotech entrepreneurs see Indian clinical trials � which can cut costs by 60 percent � as the difference between success and slow death.
India emerges as new drug trial hot spot
Biotech entrepreneurs see Indian clinical trials � which can cut costs by 60 percent � as the difference between success and slow death.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Leave a Reply
Want to join the discussion?Feel free to contribute!